EffRx obtains Swiss marketing authorization for Bronchitol in cystic fibrosis

EffRx Pharmaceuticals

4 November 2021 - EffRx Pharmaceuticals today announced that Swissmedic has approved Bronchitol (inhaled mannitol) for the treatment of cystic fibrosis in adults and in children aged 6 years and above as add‐on to other medicines.

EffRx expects the availability of Bronchitol in Switzerland in the second half of 2022.

Read EffRx Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Switzerland